hematopoietic cells In vivo efficacy of anti-MPL agonist antibody in promoting primary human

Abstract In a previous study, we generated novel anti-thrombopoietin receptor agonist antibodies as therapeutic candidates. In this report, we investigated the in vivo effects of one of these antibodies, MA01G4344U, on primary human hematopoietic cells using xenotransplantation. NOD/Shi- scid , IL-2Rγ null (NOG) mice were pretreated by total-body irradiation and transplanted with human cord blood–derived CD34+ cells. Weekly intraperitoneal injection of MA01G4344U (100 μg/mouse/week) or Peg-rhMGDF (5 μg/mouse/week) or phosphate buffered saline (PBS) was performed. Human cells in peripheral blood were analyzed by flow cytometry and bone marrow cells were analyzed by flow cytometry and colony assay. MA01G4344U successfully increased the number of human CD41+ platelets and human CD45+ cells in peripheral blood. In the bone marrow, MA01G4344U increased the number of human CD45+/CD34+ cells, which resulted in more multi-lineage progenitor cells. The efficacy of MA01G4344U in promoting primary human hematopoietic cells